🏆 Honored that our study on ARI-0001 (varnimcabtagene autoleucel) in high-risk #CLL and #RichterTransformation has been selected for an oral presentation at #ASH26 in📍New Orleans, and recognized with an ASH Abstract Achievement.
@ValentinOrtizMD @JulioDelgadoHem
Key outcomes:
FU 28.6 mo
✅ ORR 84%
✅ CR rate 66% (72% in RT)
✅ uMRD in 83% of evaluable CLL patients
✅ Median PFS 24.8 mo in CLL, and NR in RT
✅ 2-year PFS 62% overall (54% CLL, 71% RT)
✅ No relapses among RT patients achieving CR
☢️ Grade 3-4 AE: CRS 2.6%, ICANS 0%
Nil Albiol retweeted
Great to see a randomised study of CAR-T (zamto-cel) v R-GemOx, transplant ineligible relapsed DLBCL. Whilst there was EFS & PFS benefit for zamto-cel, OS the same and no obvious plateau on PFS curve. Tox of zamto is modest - all grade ICANs 11%. #lymsm
thelancet.com/journals/lanon…
It’s been a pleasure to share insights from our almost 10‑year #ARI0001 (var‑cel) program, tracing its development and compassionate use results, at the @tcddublin @stjamesdublin TSJCI 13th International Cancer Conference!
@hematoclinicbcn
Nil Albiol retweeted
Honoured to see our phase 2 trial on Varnimcabtagene autoleucel for R/R B-ALL published in the March issue of @LancetHaem. A meaningful milestone for hospital-based innovation in cell therapy.
Pleased to discuss the study with Julio Delgado in the accompanying podcast!
🩸March issue!
CD19 CAR T-cells for R/R B-cell ALL; bortezomib + vorinostat for infants with ALL; venetoclax + high-dose cytarabine + mitoxantrone for R/R AML; PROs in AML.
Cover: MDS vs AML diagnostic conundrum!
🎙️shorturl.at/T5uO1
Issue here: shorturl.at/52JcK
Nil Albiol retweeted
🚨New in Lancet Haematology:
CART19-BE-02 reports the multicentre phase 2 trial of varnimcabtagene autoleucel (var-cel), a hospital-based, point-of-care CD19 CAR T for adults with R/R B-cell precursor ALL.
sciencedirect.com/science/ar…
🔓Free access link:
authors.elsevier.com/c/1mYpe…
Nil Albiol retweeted
This Guidelines paper recommends prioritizing CAR T-cell therapy over bispecific antibodies or ADCs for eligible relapsed/refractory myeloma patients, as prior use of certain agents may reduce CAR T-cell effectiveness.
👉bit.ly/4rn5d5K
Nil Albiol retweeted
The current findings suggest that nonhematologic AIDs are prevalent in patients with chronic lymphocytic leukemia, and these patients have a better prognosis than patients who have autoimmune cytopenia.
acsjournals.onlinelibrary.wi…
@OncoAlert @miguel_argdtom @hematosantpau #leusm
Nil Albiol retweeted
Thrilled to share our new paper in Cancer on advances in CLL & Autoimmunity! 😊😊 Our comprehensive work dives into the clinical and immunologic alterations in these patients: epidemiology, prognosis, Th17/Treg cells... @gellc @hematosantpau @nilalbiol
acsjournals.onlinelibrary.wi…
Nil Albiol retweeted
CONGRESS | #ASH25 | PRESENTATION
@gabriel_brisou @paoli_calmettes shares results from a comparative analysis of axi-cel vs liso-cel as 2L therapy in real-world patients with R/R LBCL in France.
After PS-weighting, there was no significant difference in OS or PFS, however, axi-cel was associated with a higher incidence of ICANS, CRS, ICU transfers and NRM vs liso-cel.
Follow our live feed for more updates: loom.ly/POS6cqk
Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.
#lymphoma #lymsm #MedicalCongress
Nil Albiol retweeted
CONGRESS | #ASH25 | PRESENTATION
Aina Oliver-Caldes shares findings from a real-world study of patients with RRMM treated with ARI0002h (cesnicabtagene autoleucel) (N = 123).
ORR was 95%, MRG-neg rate was 91%. Any grade CRS was 63%; grade 3 CRS 1.6%. Grade 1-2 ICANS in 4% of patients, comparable to the pivotal clinical trial.
Follow our live feed for more updates: loom.ly/Z6rsHq8
Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content. A full list of supporters can be found on our website.
#mmsm #myeloma #MedicalCongress @ainitaoliver @hospitalclinic
Nil Albiol retweeted
📣SAVE THE DATE
VII edición:
"Aspectos prácticos en aplicación clínica de terapia Chimeric Antigen Receptor T-Cell (CAR-T)".
📅23-24 Oct 2025
📍Facultat de Medicina de la Universitat de Barcelona
🗣️Información e inscripciones: aulaclinic.com/cursos/1329/v……
Nil Albiol retweeted
Drug development in MZL: caring for the forgotten child
@BloodPortfolio
@c_thieblemont
#Sylvain Carras
@ComeBommier ashpublications.org/blood/ar…
Nil Albiol retweeted
🇪🇸 var-cel in R/R FL
academic anti-CD19 CAR T-cells
N = 27
CRS all grades 55%, grade 3+ 4%
3-y PFS 81%
Worth reading @Hemasphere_EHA !
onlinelibrary.wiley.com/doi/…
Our academic CAR-T (var-cel or ARI0001) from @hematoclinicbcn achieved similar efficacy to other CD19-directed products with a negligible ICANS incidence! It’s been a reality for almost 30 pts, most pf them remaining in CR to date. Congrats! onlinelibrary.wiley.com/doi/…
Check out our poster on the results of varnimcabtagene autoleucel (ARI0001) in CLL and Richter’s transformation!
Poster no. 1905
#iwCLL2025
I will also present the results of a study evaluating the use of cell-free cfDNA MRD in CLL together with my great colleague @miguel_argdtom
No. 1430 #iwCLL2025
Sure it is! Apply now!
#CRTH is just the perfect place to learn how to design a credible trial, connect with talented hematologists, and benefit from the insights of experienced mentors.
We even take time to address work-life balance!
If you’re interested, do not hesitate: apply before it’s too late!
4
364
Nil Albiol retweeted
CONGRESS | #SOHO2025 | PRESENTATION
@niravshahmd @MedicalCollege presents phase Ia results from the phase I NX-5948-301 trial of bexobrutideg (NX-5948) in patients with R/R CLL/SLL (N = 48).
Bexobrutideg was well tolerated, and responses were rapid, with an ORR of 80.9%, a median time to first response of 1.87 months.
Follow our live feed for more updates: loom.ly/rBZZxmc
#leusm #lymsm #MedicalCongress



































